TRPV1 and synovitis: In conclusion, we found that TRPV1 is a novel therapeutic target for inhibiting M1 macrophage polarization and decreasing synovitis to attenuate OA progression, unveiling a new mechanism for the topical administration of CPS for the treatment of OA.